Dokument: Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT
| Titel: | Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=71992 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20260122-142101-0 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Duplessix, Timothé [Autor] Baermann, Ben-Niklas [Autor] Hölscher, Alexander Sebastian [Autor] Tometten, Inga [Autor] Schulz, Felicitas [Autor] Munder, Stefanie [Autor] Le, Duyen B. [Autor] Jäger, Paul [Autor] Nachtkamp, Kathrin [Autor] Dietrich, Sascha [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | letermovir prophylaxis , ELISpot analysis , T-cell immunity , alloHSCT , CMV infection | |||||||
| Beschreibung: | CMV-specific immune monitoring may support individualized risk stratification after allogeneic hematopoietic stem cell transplantation (alloHSCT), but its role in the era of letermovir prophylaxis remains unclear. In this prospective single-center study, 45 CMV-seropositive alloHSCT recipients receiving letermovir prophylaxis for 100 days post-transplant were followed for 12 months. CMV-specific T-cell responses to IE-1 and pp65 were assessed by IFN-γ ELISpot on days 100 and 200, and at the time of CMV infection and follow-up. Early CMV infection occurred in 18/45 patients (40%) during prophylaxis, of which 16 (88.9%) were transient “blips” and required no pre-emptive therapy. In univariate logistic regression, early CMV infection was associated a significantly lower risk of late CMV infection (p = 0.0044). IE-1-specific responses at day 100 were significantly higher in patients without late infection (median 27.5 vs. 5.0 SFC/250,000 PBMCs; p = 0.0056), and in those with early CMV infection (p = 0.0351). T-cell responses were already detectable at the time of CMV infection and remained stable thereafter. In conclusion, early abortive CMV DNAemia during letermovir prophylaxis appears to induces rapid and durable T-cell immunity. Immune monitoring may not be required in these patients, whereas ELISpot testing at day 100 may guide risk-adapted management in those without early CMV exposure. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Duplessix, T., Bärmann, B.-N., Hölscher, A., Tometten, I., Schulz, F., Munder, S., Le, D. B., Jäger, P. S., Nachtkamp, K., Dietrich, S., Timm, J., Kobbe, G., & Lübke, N. (2025). Early CMV DNAemia during letermovir prophylaxis predicts lower risk of late CMV infection and is associated with enhanced T-cell immunity after alloHSCT. Scientific Reports, 15, Article 41154. https://doi.org/10.1038/s41598-025-27490-z | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 22.01.2026 | |||||||
| Dateien geändert am: | 22.01.2026 |
